دورية أكاديمية
The use of tofacitinib in the treatment of inflammatory bowel disease.
| العنوان: | The use of tofacitinib in the treatment of inflammatory bowel disease. |
|---|---|
| المؤلفون: | Weisshof R; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL 60637, USA., Golan MA; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL 60637, USA., Yvellez OV; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL 60637, USA., Rubin DT; Inflammatory Bowel Disease Center, University of Chicago Medicine, Chicago, IL 60637, USA. |
| المصدر: | Immunotherapy [Immunotherapy] 2018 Aug; Vol. 10 (10), pp. 837-849. Date of Electronic Publication: 2018 Apr 27. |
| نوع المنشور: | Journal Article; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Future Medicine Country of Publication: England NLM ID: 101485158 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1750-7448 (Electronic) Linking ISSN: 1750743X NLM ISO Abbreviation: Immunotherapy Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Future Medicine |
| مواضيع طبية MeSH: | Inflammatory Bowel Diseases/*drug therapy , Piperidines/*therapeutic use , Protein Kinase Inhibitors/*therapeutic use , Pyrimidines/*therapeutic use , Pyrroles/*therapeutic use, Humans |
| مستخلص: | Janus kinases (JAK) play a major role in the immunologic pathways and specifically in signal transduction in inflammatory bowel disease. Thus, they can serve as a target for new therapeutic options. Tofacitinib is a novel, first-in-class, pan-Janus kinase inhibitor. It has been found to be effective and safe in the treatment of moderate-to-severe ulcerative colitis. In this review, we will describe the drug's mechanism of action as well as the clinical evidence for its effectiveness in treating patients with inflammatory bowel disease. |
| فهرسة مساهمة: | Keywords: Crohn's disease; JAK inhibitors; inflammatory bowel disease; tofacitinib; ulcerative colitis |
| المشرفين على المادة: | 0 (Piperidines) 0 (Protein Kinase Inhibitors) 0 (Pyrimidines) 0 (Pyrroles) 87LA6FU830 (tofacitinib) |
| تواريخ الأحداث: | Date Created: 20180428 Date Completed: 20190722 Latest Revision: 20190722 |
| رمز التحديث: | 20240628 |
| DOI: | 10.2217/imt-2018-0015 |
| PMID: | 29701124 |
| قاعدة البيانات: | MEDLINE |
PDF full text from Publisher 
Full Text Finder | تدمد: | 1750-7448 |
|---|---|
| DOI: | 10.2217/imt-2018-0015 |